New Tiandi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this announcement is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
On February 26, 2026, the Company held the tenth meeting of the sixth Board of Directors, which reviewed and approved the proposal on the confirmation of using part of the idle raised funds and own funds for cash management, agreeing to the Company's confirmation of using part of the idle raised funds and own funds for cash management. The specific situation is announced as follows:
1. Basic Situation of Raised Funds
According to the approval from the China Securities Regulatory Commission on the registration of the initial public offering of Henan New Tiandi Pharmaceutical Co., Ltd. (Zheng Jian Xu Ke [2022] No. 1911), the Company publicly issued 33,360,000 A-shares with a par value of RMB 1.00 each at an issue price of RMB 27.00 per share, raising a total of RMB 900,720,000.00. After deducting the total issuance costs related to the raised funds amounting to RMB 85,154,160.95 (excluding VAT), the net raised funds amount to RMB 815,565,839.05. The above raised funds were verified by KPMG Huazhen LLP and a verification report (KPMG Huazhen Yan Zi No. 2201583) was issued on November 11, 2022.
2. Usage of Raised Funds
The specific usage plan for the raised funds disclosed in the prospectus for the initial public offering of Henan New Tiandi Pharmaceutical Co., Ltd. is as follows:
| No. | Project Name | Total Investment Amount | Proposed Amount of Raised Funds |
|---|---|---|---|
| 1 | Construction Project for 120 Tons of Raw Materials | 26,420.48 | 26,420.48 |
| 2 | R&D Center Construction Project | 12,074.67 | 12,074.67 |
| 3 | Supplementing Working Capital | 20,000.00 | 20,000.00 |
| Total | 58,495.15 | 58,495.15 |
On May 23, 2023, the Company held the thirteenth meeting of the fifth Board of Directors and the tenth meeting of the fifth Supervisory Board, and on June 8, 2023, the second extraordinary general meeting of 2023, which reviewed and approved the proposal on using the excess raised funds to invest in the construction of an intelligent specialty raw material pharmaceutical supporting industrial chain project, agreeing to use RMB 100 million of excess raised funds for this project. After the adjustment in the usage of raised funds, the specific usage plan is as follows:
| No. | Project Name | Total Investment Amount | Proposed Amount of Raised Funds |
|---|---|---|---|
| 1 | Construction Project for 120 Tons of Raw Materials | 26,420.48 | 26,420.48 |
| 2 | R&D Center Construction Project | 12,074.67 | 12,074.67 |
| 3 | Intelligent Specialty Raw Material Pharmaceutical Supporting Industrial Chain Project | 10,000.00 | 10,000.00 |
| 4 | Supplementing Working Capital | 20,000.00 | 20,000.00 |
| Total | 68,495.15 | 68,495.15 |
3. Status of Fund Investment Projects
As of now, the status of the Company's fund investment projects is as follows:
| No. | Project Name | Implementation Status | Date of Reaching Usable Status |
|---|---|---|---|
| 1 | Construction Project for 120 Tons of Raw Materials | Completed | November 2, 2025 |
| 2 | R&D Center Construction Project | Completed | March 2025 |
| 3 | Intelligent Specialty Raw Material Pharmaceutical Supporting Industrial Chain Project | Completed | November 2025 |
| 4 | Supplementing Working Capital | - | - |